I posted this several years ago - but unfortunatelly Sanofi wasn't really interested
-----------------------------
Einstein’s wise dictum “invert, always invert”
To pose a question: If inhalable insulin was invented first and another pharmaceutical company developed an insulin treatment whose key differentiation was that it was injectable, how many people would switch?
Our research could not be any clearer: virtually none.
Our research could not be any clearer: puppets are supported by strings of corruption
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARYFINANCIAL DISCLOSURESDr. Jeffrey R. Garber reports that he does not have any relevant financial relationships with any commercial interests.
Dr. Alan J. Garber reports that he is a consultant for
Novo Nordisk and Intarcia
Dr. W. Timothy Garvey reports that he is a consultant for AstraZeneca, Janssen, Eisai, Takeda,
Novo Nordisk, Alexion, and Merck. He has also received research grants from Merck, Weight Watchers,
Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer,
Novo Nordisk, and Elcelyx. Dr. Garvey is a shareholder in ISIS Pharmaceuticals, Novartis, Bristol Myers Squibb, Pfizer, Merck, and
Eli Lilly.
Dr. Martin Julian Abrahamson reports that he is a consultant for
Novo Nordisk, WebMD Health Services, and Health IQ.
Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any commercial interests.
Dr. Lawrence Blonde reports that he is a consultant for AstraZeneca, GlaxoSmithKline, Intarcia, Janssen Pharmaceuticals, Inc., Merck & Co., Inc.,
Novo Nordisk, and
Sanofi. He is also a speaker for AstraZeneca, Janssen Pharmacueticals, Inc., Merck & Co., Inc.,
Novo Nordisk, and
Sanofi. Dr. Blonde has received research grant support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co.,
Novo Nordisk, and
Sanofi.Dr. George Grunberger reports that he has received speaker honoraria from
Eli Lilly, BI-Lilly,
Novo Nordisk, Sanofi, Janssen, and AstraZeneca. He has received research funding from AstraZeneca
, Eli Lilly, Lexicon, and Medtronic.
Dr. Zachary Bloomgarden reports that he is a consultant for AstraZeneca, Johnson & Johnson, Merck, Intarcia, and Novartis. He is also a speaker for Merck, AstraZeneca, and Johnson & Johnson. He is a stock shareholder for Allergan, Pfizer, Zimmer Biomet, and Novartis.
Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen,
Eli Lilly, Eisai, Intarcia, Merck,
Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, BI-Lilly,
Janssen,
Novo Nordisk,
Sanofi, and Regeneron. Dr. Handelsman has also received grant support from Amgen, AstraZeneca, BI, Esperion, Grifols, Hamni, GlaxoSmithKline, Lexicon, Merck,
Novo Nordisk, and
Sanofi.Dr. Michael A. Bush reports that he is an Advisory Board Consultant for Janssen and
Eli Lilly. He is on the speaker’s bureau for Takeda
, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim.
Dr. Irl B. Hirsch reports that he is a consultant for Abbott Diabetes Care, Roche, Intarcia, and Valeritas
. Dr. Samuel Dagogo-Jack reports that he is a consultant for Merck,
Novo Nordisk, Janssen, and Boehringer Ingelheim. He has received research grants from Amgen. Additionally, AstraZeneca,
Novo Nordisk, and Boehringer Ingelheim have clinical trial contracts with the University of Tennessee for studies in which Dr. Dagogo-Jack serves as the Principal Investigator or Co-Investigator.
Dr. Paul S. Jellinger reports that he has received speaker honoraria from BI-Lilly, AstraZeneca
, Novo Nordisk, Merck, and Amgen.
Dr. Ralph Anthony DeFronzo reports that he is on the Advisory Board for AstraZeneca,
Novo Nordisk, Janssen, Boehringer Ingelheim, Intarcia, and Ecelyx. He is also a speaker for
Novo Nordisk and AstraZeneca. Dr. DeFronzo has received research grant support from Boehringer Ingelheim, Takeda, Janssen, and AstraZeneca.
Dr. Janet B. McGill reports that she is a consultant for Boehringer Ingelheim, Janssen, Merck,
Novo Nordisk, Calibra, Dynavax, Valertias, and Intarcia. She is also a speaker for Janssen. Dr. McGill has received research grant support from Novartis, Dexcom, Bristol Myers Squibb, and Lexicon.
Dr. Daniel Einhorn reports that he is a consultant for
Eli Lilly, Takeda,
Novo Nordisk, Adocia,
Sanofi, Epitracker, Janssen, Intarcia, Glysens, and Freedom-Meditech and has received research grant support from
Novo Nordisk, Eli Lilly, AstraZeneca, Eisai, Janssen, and
Sanofi. He is also a shareholder of Halozyme.
Dr. Paul D. Rosenblit reports that he is a consultant for AstraZeneca and a speaker for AstraZeneca (Bristol Myers Squibb), Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck,
Novo Nordisk, and Takeda. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Ionis,
Eli Lilly, Lexicon, Merck,
Novo Nordisk, Orexigen, Pfizer, and
Sanofi.
Dr. Vivian A. Fonseca reports that he is a consultant for Takeda,
Novo Nordisk, Sanofi, Eli Lily, Pamlabs, AstraZeneca, Abbott, Boehringer Ingelheim, Janssen and Intarcia. He is a speaker for Takeda, AstraZeneca, and
Sanofi. Dr. Fonseca has also received research grants from
Novo Nordisk, Asahi
, Eli Lilly, Abbott, Endo Barrier, Bayer, and Gilead.
Dr. Guillermo E. Umpierrez reports that he is a consultant for
Sanofi and Glytec. He also received research grant support from Merck,
Sanofi, Boehringer Ingelheim, AstraZeneca, and
Novo Nordisk.Dr. Jeffrey I. Mechanick reports that he is a consultant for Abbott Nutrition International.
Dr. Stephanie Adams reports that she does not have any relevant financial relationships with any commercial interests.
www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf
